We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New AI Software for Brain Bleed Diagnosis Receives FDA Clearance

By HospiMedica International staff writers
Posted on 20 Nov 2018
The US Food and Drug Administration (FDA) has given 510(k) clearance to the Accipio Ix intracranial hemorrhage (ICH) detection software developed by MaxQ AI (Tel Aviv, Israel), a clinical diagnostics intelligence platform company.

This will provide healthcare providers and physicians in acute care settings with access to the artificial intelligence (AI) software which has been designed to aid in prioritizing the clinical assessment of adult non-contrast head computed tomography (CT) cases that exhibit indications of ICH, commonly known as a brain bleed.

Image: Product representations of the Accipio ICH detection software.
Image: Product representations of the Accipio ICH detection software.

MaxQ AI develops clinical diagnostic intelligent software solutions that enable timely and more accurate diagnosis as well as allow physicians to provide 'smarter care' with AI clinical insights. The company’s Accipio Ix ICH detection software leverages AI technology to automatically analyze non-contrast head CT images without workflow impact to the reader, altering the original series or storing Protected Health Information (PHI). Accipio Ix, part of MaxQ's Accipio INSIGHT platform, is designed to be highly sensitive to the presence of ICH, identifying and prioritizing patients with ICH for the treating physician. The AI-powered software provides the capability for rapid escalation and prioritization of the patient and can be natively integrated into CT and PACS systems using the imaging industry-standard DICOM, installed both on-premise and cloud-capable.

"MaxQ's Accipio application, of which Accipio Ix is the first part of the ecosystem, provides physicians with actionable intelligence, improving their future ability to make a timely, accurate and more confident diagnosis of a brain bleed," said Gene Saragnese, Chairman and CEO of MaxQ AI. "Accipio Ix's ability to greatly increase suspected bleed detection, improve escalation and time to review is a game-changer. Further, our partnerships with top CT and PACS companies, including GE Healthcare, Samsung Neurologica and other organizations prior announced, make deployment and adoption of Accipio straightforward."

Related Links:
MaxQ AI


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Multilevel Self-Loading Stretcher
CARRERA XL

Latest AI News

AI-Powered Algorithm to Revolutionize Detection of Atrial Fibrillation

AI Diagnostic Tool Accurately Detects Valvular Disorders Often Missed by Doctors

New Model Predicts 10 Year Breast Cancer Risk